PharmaReliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis

Roberta Gualtierotti, Francesca Ingegnoli, Rebecca Two, Pier Luigi Meroni, Dinesh Khanna, Giuditta Adorni, Andrea Becciolini, Teresa Ciavarella, Giovanni Marfia, Antonella Murgo, Luciana Scalone, Nicola Ughi, Silvana Zeni, study group VERITAS study group

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. To test the acceptability, feasibility, reliability and validity of the Italian translated version of the UCLA Scleroderma Clinical Trial Consortium GIT (UCLA-SCTC GIT) 2.0. Gastrointestinal tract (GIT) involvement is frequent in systemic sclerosis (SSc). The UCLA-SCTC GIT 2.0 is a validated instrument for measuring the presence and impact of GIT symptoms in SSc patients. Methods. Acceptability and feasibility of the questionnaire were evaluated based on the input from the patients. Internal consistency was evaluated by Cronbach's alpha. External consistency was measured by comparing with the Short Form (SF)-36 and EQ-5D by Spearman's rho, meaningful if =0.30. Results. Sixty-two consecutive SSc patients (mean age 60.6) were recruited, 88.5% were female. The UCLA-SCTC GIT 2.0 was well accepted. Percentage of missing data in UCLA-SCTC GIT total score was 2 %. Internal consistency was acceptable (alpha ≥0.70) for all domains. Cronbach's alpha was ≥0.70 for all domains. UCLA-SCTC GIT 2.0 discriminated between patients with or without gastroesophageal reflux disease whether diagnosed clinically or by objective testing (p <0.01 for both). UCLA-SCTC GIT emotional well-being was correlated with the conceptually equivalent SF-36 mental health domains (correlation coefficient > 0.35) and with the EQ-5D usual activities domain (0.38), thus reflecting the impact on everyday activities. The distention/bloating domain strongly correlated with the EQ-5D anxiety/depression domain (0.51) and reflux domain with role emotional of SF-36 (0.44). Conclusion. This is the first validation study of the Italian version of UCLA-SCTC GIT 2.0. Our data support its feasibility, reliability, and validity in Italian SSc patients.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalClinical and Experimental Rheumatology
Volume33
Publication statusPublished - 2015

Keywords

  • Diarrhoea
  • EQ-5D
  • Gastroesophageal reflux
  • Gastrointestinal tract
  • Health-related quality of life
  • Questionnaire
  • Scleroderma
  • SF-36
  • Systemic sclerosis
  • UCLA-GIT 2.0

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Fingerprint

Dive into the research topics of 'PharmaReliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis'. Together they form a unique fingerprint.

Cite this